Cell‐targeting and cell‐penetrating peptides for delivery of therapeutic and imaging agents

Juliano, Rudolph L.; Alam, Rowshon; Dixit, Vidula; Kang, Hyun Min

doi:10.1002/wnan.4

Cited by 66 publications

(47 citation statements)

References 120 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Receptor-targeted nanocarriers aimed at specific tissues and cells have been investigated by many researchers, and the findings have accelerated the application of nanotechnology in medicine (referred to as nanomedicine) (Juliano et al, 2009;. However, these techniques have been limited to developing nanocarriers that target a specific organelle, such as the nucleus, mitochondria, golgi apparatus, endoplasmic reticulum, etc., which are promising targets for therapeutic drugs.…”

Section: Introductionmentioning

confidence: 99%

Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier

Yamada

Harashima

2013

Mitochondrion

View full text Add to dashboard Cite

The focus of this study was on the development of a nano carrier targeted to mitochondria, a promising therapeutic drug target. We synthesized a lipid derivative that is conjugated with a mitochondrial targeting signal peptide (MTS), which permits the selective delivery of certain types of proteins to mitochondria.We then explored the use of an innovative technology in which MTS and the MITO-Porter were integrated.The latter is a liposome that delivers cargos to mitochondria via membrane fusion. The results indicate that the combination of MTS and the MITO-Porter would be useful for selective mitochondrial delivery via membrane fusion.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier

Yamada

Harashima

2013

Mitochondrion

View full text Add to dashboard Cite

show abstract

“…13 Cell-penetrating peptides (CPP) are emerging as attractive drug delivery systems because of their ability to transport a range of cargoes across the cell membrane, ranging from small molecules to proteins and supramolecular particles. [14][15][16] For CPP, more must be done to investigate the precise mechanism of action of these molecules, and to improve the efficiency with which they move from the plasma membrane or endomembrane compartments to the cytosol. The same is true regarding the selectivity of CPP.…”

mentioning

confidence: 99%

Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model

Yuan¹,

Liu²,

Chen³

et al. 2013

IJN

View full text Add to dashboard Cite

Background The purpose of this study was to evaluate the antitumor effect of cell-penetrating peptide-coated tripterine-loaded nanostructured lipid carriers (CT-NLC) on prostate tumor cells in vitro and in vivo. Methods CT-NLC were developed to improve the hydrophilicity of tripterine. The antiproliferative effects of CT-NLC, tripterine-loaded nanostructured lipid carriers (T-NLC), and free tripterine in a human prostatic carcinoma cell line (PC-3) and a mouse prostate carcinoma cell line (RM-1) were evaluated using an MTT assay. The advantage of CT-NLC over T-NLC and free tripterine with regard to antitumor activity in vivo was evaluated in a prostate tumor-bearing mouse model. The induced tumor necrosis factor-alpha and interleukin-6 cytokine content was investigated by enzyme-linked immunosorbent assay to determine the effect of CT-NLC, T-NLC, and free tripterine on immune responses. Histologic and TUNEL assays were carried out to investigate the mechanisms of tumor necrosis and apoptosis. Results CT-NLC, T-NLC, and free tripterine showed high antiproliferative activity in a dose-dependent manner, with an IC 50 of 0.60, 0.81, and 1.02 μg/mL in the PC-3 cell line and 0.41, 0.54, and 0.89 μg/mL in the RM-1 cell line after 36 hours. In vivo, the tumor inhibition rates for cyclophosphamide, high-dose (4 mg/kg) and low-dose (2 mg/kg) tripterine, high-dose (4 mg/kg) and low-dose (2 mg/kg) T-NLC, high-dose (4 mg/kg) and low-dose (2 mg/kg) CT-NLC were 76.51%, 37.07%, 29.53%, 63.56%, 48.25%, 72.68%, and 54.50%, respectively, showing a dose-dependent pattern. The induced tumor necrosis factor-alpha and interleukin-6 cytokine content after treatment with CT-NLC and T-NLC was significantly higher than that of high-dose tripterine. Moreover, CT-NLC showed the expected advantage of inducing necrosis and apoptosis in prostate tumor cells. Conclusion CT-NLC noticeably enhanced antitumor activity in vitro and in vivo and showed dramatically improved cytotoxicity in normal cells in comparison with free tripterine. In summary, CT-NLC could be used as a promising drug delivery system for the treatment of prostate cancer.

show abstract

“…The first method was mediated via encapsulation of antibodies within the liposomes (Ab-DeliverIN™), which represents one of the oldest nanotechnologies for drug delivery [27] . The second method was through conjugation of the antibody with membrane transporting peptides, also called cell-penetrating peptides (CPPs), which represents a novel strategy to deliver biological active molecules into living cells [28] . RAW264.7 cells was used because macrophages are highly sensitive to ricin intoxication due to abundant mannose receptors present on the cell surface that bind ricin, and macrophage apoptosis had been shown to be one of the early events that occurred in the lungs after ricin inhalation [29] .…”

Section: Discussionmentioning

confidence: 99%

Protective effects of anti-ricin A-chain antibodies delivered intracellularly against ricin-induced cytotoxicity

Fan²,

Martiniuk³

et al. 2010

WJBC

View full text Add to dashboard Cite

AIM:To evaluate the ability of anti-ricin A-chain antibodies, delivered intracellularly, to protect against ricininduced cytotoxicity in RAW264.7 cells. METHODS:Anti-deglycosylated ricin A-chain antibody and RAC18 anti-ricin A-chain monoclonal antibody were delivered intracellularly by encapsulating in liposomes or via conjugation with the cell-penetrating MTS-transport peptide. RAW264.7 cells were incubated with these antibodies either before or after ricin exposure. The changes in cytotoxicity were estimated by MTT assay. Co-localization of internalized antibody and ricin was evaluated by fluorescence microscopy. RESULTS:Internalized antibodies significantly increased cell viability either before or after ricin exposure compared to the unconjugated antibodies. Fluorescence microscopy confirmed the co-localization of internalized antibodies and ricin inside the cells.

show abstract

Cell‐targeting and cell‐penetrating peptides for delivery of therapeutic and imaging agents

Cited by 66 publications

References 120 publications

Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier

Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier

Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model

Protective effects of anti-ricin A-chain antibodies delivered intracellularly against ricin-induced cytotoxicity

Contact Info

Product

Resources

About